Acumen's Alzheimer's Drug Passes Initial Safety Test

Acumen Pharmaceuticals announced today, Sunday, that an experimental drug for treating Alzheimer's developed by the company has successfully passed an initial safety test and will advance to larger trials. This drug targets a new form of the toxic protein component beta-amyloid in the brain. The company stated that the drug ACI193 was well received in the first trial on patients. Results of the study, conducted on a random sample of 62 patients showing early symptoms of Alzheimer's, were presented at the International Alzheimer's Association conference in Amsterdam. The study included a comparison between a group of participants given the drug and another group given a placebo. Dr. Eric Simers, Chief Medical Officer at Acumen, said in an interview that the new drug developed by the company targets and binds to small aggregates of beta-amyloid, a toxic soluble version of the amyloid protein that forms brain plaques associated with the disease. In Acumen’s trial, the company mentioned that those receiving higher doses of the new drug showed reduced levels of amyloid plaques after a period of six to twelve weeks, indicating that the drug could be administered to patients via intravenous injection once a month.